| 27.25 0.12 (0.44%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.1 | 1-year : | 39.83 |
| Resists | First : | 29.2 | Second : | 34.1 |
| Pivot price | 25.62  |
|||
| Supports | First : | 20.35 | Second : | 14.89 |
| MAs | MA(5) : | 27.17  |
MA(20) : | 24.02 |
| MA(100) : | 16.07 |
MA(250) : | 15.39 |
|
| MACD | MACD : | 2.7 |
Signal : | 2.7 |
| %K %D | K(14,3) : | 78.4 |
D(3) : | 79.8 |
| RSI | RSI(14): 70.6 |
|||
| 52-week | High : | 30.51 | Low : | 5.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ORKA ] has closed below upper band by 33.3%. Bollinger Bands are 128.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.72 - 27.85 | 27.85 - 27.97 |
| Low: | 26.44 - 26.6 | 26.6 - 26.74 |
| Close: | 27 - 27.25 | 27.25 - 27.48 |
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Fri, 24 Oct 2025
Pipeline Progress on Monoclonal Antibodies Might Change The Case For Investing In Oruka Therapeutics (ORKA) - simplywall.st
Fri, 24 Oct 2025
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: 59% Potential Upside Fuels Investor Excitement - DirectorsTalk Interviews
Fri, 17 Oct 2025
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 62.73% Upside in the Biotech Arena - DirectorsTalk Interviews
Sun, 12 Oct 2025
Is Oruka Therapeutics’ (ORKA) Fundraising Spree a Sign of Strategic Flexibility or Underlying Caution? - Sahm
Fri, 10 Oct 2025
Oruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M Offering - Yahoo Finance
Wed, 17 Sep 2025
Oruka Therapeutics Announces $180 Million Private Placement - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 78.5 (%) |
| Shares Short | 3,610 (K) |
| Shares Short P.Month | 3,200 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -96 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 2.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.75 |
| Dividend | 19.36 |
| Forward Dividend | 0 |
| Dividend Yield | 71% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|